These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 872149)

  • 21. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy.
    Benjamin RS; Mason JW; Billingham ME
    Cancer Treat Rep; 1978 Jun; 62(6):935-9. PubMed ID: 667871
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
    Hortobagyi GN; Holmes FA; Theriault RL; Rahman Z; Buzdar AU
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-13-S11-19. PubMed ID: 9314293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
    Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
    Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adriamycin cardiotoxicity amelioration by alpha-tocopherol.
    Krivit W
    Am J Pediatr Hematol Oncol; 1979; 1(2):151-3. PubMed ID: 543510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
    Herman EH; Lipshultz SE; Rifai N; Zhang J; Papoian T; Yu ZX; Takeda K; Ferrans VJ
    Cancer Res; 1998 Jan; 58(2):195-7. PubMed ID: 9443390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adriamycin: cardiotoxicity].
    Gamna G; Lovisetto P; Pochnettino G; Biarese V
    Boll Soc Ital Cardiol; 1974; 19(7):633-70. PubMed ID: 4464961
    [No Abstract]   [Full Text] [Related]  

  • 27. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
    Ewer MS; Jaffe N; Ried H; Zietz HA; Benjamin RS
    Med Pediatr Oncol; 1998 Dec; 31(6):512-5. PubMed ID: 9835904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective monitoring for anthracycline cardiotoxicity: an introduction.
    McGuire WP
    Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858
    [No Abstract]   [Full Text] [Related]  

  • 29. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.
    Carver JR; Schuster SJ; Glick JH
    J Clin Oncol; 2008 Jul; 26(19):3122-4. PubMed ID: 18591552
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Local administration of adriamycin (ADM) for malignant pleural effusion and pericardiac effusion in breast cancer].
    Saisho S; Saeki T; Takashima S; Aogi K; Ohsumi S
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2063-8. PubMed ID: 14712766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
    Lehotay DC; Levey BA; Rogerson BJ; Levey GS
    Cancer Treat Rep; 1982 Feb; 66(2):311-6. PubMed ID: 6120040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiotoxicity of anthracyclines. Apropos of 12 pediatric cases].
    Favrot MC; Pouyau G; Souillet G; Philip T; Bozzio A; Philippe N
    Pediatrie; 1981 Sep; 36(6):437-50. PubMed ID: 6947199
    [No Abstract]   [Full Text] [Related]  

  • 34. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.
    Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
    Breast Cancer Res Treat; 2008 Feb; 107(3):443-50. PubMed ID: 17978870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Possible role of adriamycinol in the cardiotoxicity induced by adriamycin in the rat].
    Danesi R; Del Tacca M; Ducci M; Bernardini C; Romanini A
    G Ital Chemioter; 1985; 32(1):31-3. PubMed ID: 3830790
    [No Abstract]   [Full Text] [Related]  

  • 37. [Liposomal adriamycin: preparation, administration, and toxicity monitoring. Nursing aspects].
    Panzolini S
    Suppl Tumori; 2004; 3(4):S120. PubMed ID: 15206235
    [No Abstract]   [Full Text] [Related]  

  • 38. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Optimal administration schedules of antineoplastic antibiotics based on their pharmacokinetics, with special reference to bleomycins and anthracyclines].
    Ota K; Goto T; Fukushima M; Ariyoshi Y
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1352-61. PubMed ID: 6191712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
    Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
    J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.